Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.
Bone metastasis is an important factor for determining the appropriate treatment for patients with lung cancer. The cross-linked N-terminal telopeptide of type I collagen (NTx) is a metabolite of type I collagen, the main constituent of the bone matrix. Urinary NTx is recognized as a useful marker of bone metastasis, but the application of serum NTx and its cutoff value for determining bone metastasis from lung cancer have not been characterized. We measured serum NTx by enzyme-linked immunosorbent assay of individuals who underwent staging during hospitalization for initial treatment of lung cancer in our department and compared the NTx levels with the presence of bone metastasis in staging. The study included 166 patients with lung cancer (128 men and 38 women), including 85 adenocarcinoma, 42 squamous cell carcinoma, 32 small-cell carcinoma, and 7 other cancer types. Bone metastasis was present in 73 cases. The average/median serum NTx of bone metastasis (+) and bone metastasis (-) was 27.8/23.8 and 17.1/16.5 nmol bone collagen equivalents/L, respectively. There was an intentional difference with P < 0.001. The cutoff value of the serum NTx level indicating bone metastasis from lung cancer was estimated using the receiver operating characteristics curve. The optimal cutoff value was found to be 22.0 (sensitivity: 61.6%, specificity: 89.2%). The results of univariate and multivariate analysis revealed that the serum NTx levels were significantly related to bone metastasis from lung cancer (P < 0.001). Measurement of serum NTx levels provides a simple diagnostic marker of bone metastasis from lung cancer.
Department of Thoracic Malignancy, Osaka Prefectural Hospital Organization, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino 3-7-1, Habikino, Osaka 583-8588, Japan. moto19781205@yahoo.co.jp
Motohiro
M
Tamiya
Hidekazu
H
Suzuki
Masashi
M
Kobayashi
Shinji
S
Sasada
Norio
N
Okamoto
Naoko
N
Morishita
Tomomi
T
Yasue
Yuka
Y
Matsuura
Tomonori
T
Hirashima
Ichiro
I
Kawase
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000556:secondary*; D024042:Collagen Type I / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010455:Peptides / Q000097:blood*; D012372:ROC Curve; D012680:Sensitivity and Specificity; D055815:Young Adult
D014408:Biomarkers, Tumor; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide
J Pharm Biomed Anal. 2004 Mar 1;34(4):827-32
15019061
Bone. 2000 Mar;26(3):241-7
10709996
J Clin Oncol. 2005 Aug 1;23(22):4925-35
15983391
J Thorac Oncol. 2009 Oct;4(10):1280-8
19701109
Clin Chem. 1993 Apr;39(4):614-8
8472354
Lancet. 1983 Sep 10;2(8350):613-6
6136757
J Clin Endocrinol Metab. 1994 Sep;79(3):730-5
8077353
Cancer. 2008 Jul 1;113(1):193-201
18459173
Cancer. 1997 Oct 15;80(8 Suppl):1588-94
9362426
J Clin Endocrinol Metab. 1995 Jan;80(1):97-103
7829646
Cancer. 2001 Apr 15;91(8):1487-93
11301396
Anticancer Res. 1996 Jul-Aug;16(4B):2221-3
8694547
J Cancer. 2010 Jun 28;1:80-92
20842228
Calcif Tissue Int. 1998 Aug;63(2):102-6
9685512
Crit Rev Clin Lab Sci. 1994;31(3):197-293
7818774
J Clin Endocrinol Metab. 1984 Jan;58(1):110-20
6227628
Korean J Lab Med. 2007 Apr;27(2):96-101
18094558